Collplant biotechnologies provides business updates and first quarter 2022 financial results

Co-development of rhcollagen-based dermal and soft tissue filler products with abbvie is advancing according to plan launch of large animal study for company's 3d bioprinted regenerative breast implant program is on track for q2 2022 initiate development of a 3d bioprinted tissue model of the human intestine to support drug discovery and personalized medicine for inflammatory bowel diseases in q3 2022 reports strong balance sheet with cash and cash equivalents of $41m as of march 31, 2022 rehovot, israel , may 26, 2022 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended march 31, 2022. "collplant continues to make important progress executing our internal pipeline and partnered programs, including our strategic agreement with abbvie to co-develop dermal and soft fillers using our proprietary collagen technology.
CLGN Ratings Summary
CLGN Quant Ranking